TW202304951A - 結合鐵調素模擬物 - Google Patents
結合鐵調素模擬物 Download PDFInfo
- Publication number
- TW202304951A TW202304951A TW111112892A TW111112892A TW202304951A TW 202304951 A TW202304951 A TW 202304951A TW 111112892 A TW111112892 A TW 111112892A TW 111112892 A TW111112892 A TW 111112892A TW 202304951 A TW202304951 A TW 202304951A
- Authority
- TW
- Taiwan
- Prior art keywords
- lys
- substituted
- cys
- solvate
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163169538P | 2021-04-01 | 2021-04-01 | |
| US202163169533P | 2021-04-01 | 2021-04-01 | |
| US202163169527P | 2021-04-01 | 2021-04-01 | |
| US63/169,538 | 2021-04-01 | ||
| US63/169,533 | 2021-04-01 | ||
| US63/169,527 | 2021-04-01 | ||
| US202263325323P | 2022-03-30 | 2022-03-30 | |
| US63/325,323 | 2022-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202304951A true TW202304951A (zh) | 2023-02-01 |
Family
ID=83456776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111112892A TW202304951A (zh) | 2021-04-01 | 2022-04-01 | 結合鐵調素模擬物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250277012A1 (https=) |
| EP (1) | EP4314017A4 (https=) |
| JP (1) | JP2024513392A (https=) |
| AU (1) | AU2022249095A1 (https=) |
| CA (1) | CA3213688A1 (https=) |
| TW (1) | TW202304951A (https=) |
| WO (1) | WO2022212696A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2968443T3 (da) | 2013-03-15 | 2021-12-06 | Protagonist Therapeutics Inc | Hepcidinanaloger og anvendelser deraf |
| PT3143037T (pt) | 2014-05-16 | 2021-09-24 | Protagonist Therapeutics Inc | Antagonistas peptídicos tioéter de integrina alfa4beta7 |
| US9624268B2 (en) | 2014-07-17 | 2017-04-18 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| EP3749345A4 (en) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
| HRP20250769T1 (hr) | 2020-01-15 | 2025-08-29 | Janssen Biotech, Inc. | Peptidni inhibitori receptora za interleukin-23 i njihova uporaba u liječenju upalnih bolesti |
| AU2021209086A1 (en) | 2020-01-15 | 2022-08-04 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| WO2023288019A2 (en) | 2021-07-14 | 2023-01-19 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of interleukin-23 receptor |
| EP4472996A4 (en) * | 2022-02-02 | 2025-11-26 | Protagonist Therapeutics Inc | Conjugated hepcidin mimetics |
| EP4472995A4 (en) * | 2022-02-02 | 2025-11-19 | Protagonist Therapeutics Inc | Conjugated hepcidin mimetics |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040152868A1 (en) * | 2001-03-30 | 2004-08-05 | Larsen Bjarne Due | Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease |
| DK2968443T3 (da) * | 2013-03-15 | 2021-12-06 | Protagonist Therapeutics Inc | Hepcidinanaloger og anvendelser deraf |
| KR20170043509A (ko) * | 2014-06-27 | 2017-04-21 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | 헵시딘 및 미니-헵시딘 유사체 및 그의 용도 |
| US20190002503A1 (en) * | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| WO2018128828A1 (en) * | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Novel hepcidin mimetics and uses thereof |
| EP3749345A4 (en) * | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
| US20210061872A1 (en) * | 2019-09-03 | 2021-03-04 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| IL299530A (en) * | 2020-07-28 | 2023-02-01 | Protagonist Therapeutics Inc | Psidine is a conjugated mimetic |
-
2022
- 2022-03-31 AU AU2022249095A patent/AU2022249095A1/en active Pending
- 2022-03-31 WO PCT/US2022/022809 patent/WO2022212696A1/en not_active Ceased
- 2022-03-31 US US18/284,835 patent/US20250277012A1/en active Pending
- 2022-03-31 CA CA3213688A patent/CA3213688A1/en active Pending
- 2022-03-31 JP JP2023560497A patent/JP2024513392A/ja active Pending
- 2022-03-31 EP EP22782206.1A patent/EP4314017A4/en active Pending
- 2022-04-01 TW TW111112892A patent/TW202304951A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4314017A4 (en) | 2025-09-10 |
| JP2024513392A (ja) | 2024-03-25 |
| EP4314017A1 (en) | 2024-02-07 |
| US20250277012A1 (en) | 2025-09-04 |
| CA3213688A1 (en) | 2022-10-06 |
| WO2022212696A1 (en) | 2022-10-06 |
| AU2022249095A1 (en) | 2023-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11472842B2 (en) | Analogues of hepcidin mimetics with improved in vivo half lives | |
| TW202304951A (zh) | 結合鐵調素模擬物 | |
| JP2026012422A (ja) | コンジュゲート型ヘプシジン模倣体 | |
| JP7849383B2 (ja) | コンジュゲートされたヘプシジン模倣物 | |
| EP4501952A2 (en) | Conjugated hepcidin mimetics | |
| WO2022212698A1 (en) | Conjugated hepcidin mimetics | |
| WO2023150630A2 (en) | Conjugated hepcidin mimetics | |
| WO2023150618A2 (en) | Conjugated hepcidin mimetics | |
| CN117730089A (zh) | 结合型铁调素模拟物 | |
| CN117813313A (zh) | 结合型铁调素模拟物 | |
| CN116457000A (zh) | 缀合的铁调素模拟物 | |
| EA053112B1 (ru) | Конъюгированные миметики гепсидина | |
| EA048412B1 (ru) | Конъюгированные миметики гепсидина |